Latest on Pharmaceutical Industry


Japan's Otsuka aims to apply for TB drug approval in India in 90 days

Japanese drugmaker Otsuka Pharmaceutical aims to apply for approval of its tuberculosis (TB) drug delamanid in India within three months, a senior company official said, as calls grow for expanded access to the life-savi..Read More...

Novartis to speed up bid for MS drug approval, changes target

Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease. Wit..Read More...



Pharmaceutical Lyophilisation Summit

Hotel Eurostars Berlin,
Vonlanthen Group


2nd Healthcare Asia Pacific Summit 2017

Four Points by Sheraton Singapore, Riverview,

Press Releases

Crescita Therapeutics™ Announces Agreement with Taro Pharmaceuticals for Pliaglis®

Crescita Therapeutics Inc a commercial dermatology company with a portfolio of nonprescription skincare products and prescription drugs today announced it has entered into a development and commercialization license agre.. Read More...

Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR®

Glenmark Pharmaceuticals a global pharmaceutical company today announced that the US Food and Drug Administration FDA cleared the company39s Investigational New Drug IND application to initiate a firstinhuman study of GB.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics